Emerging biotechnologies: full report - Nuffield Council on Bioethics

E m e r g i n g b i o t e c h n o l o g i e s
public engagement 5.52–5.54, 5.53–5.55
range of competence 5.31
range of expertise 5.31
<strong>report</strong>ing of deliberations 5.46, 10.8
virtue of candour 4.50–4.51
vs non-experts 5.30
see also researchers
sectional interests 4.38, 5.63
influences over the media 5.14–5.16, 5.19
of private sector scientists 9.7
transcending 5.27
semiconductors 3.23, 6.30–6.31
serendipity 3.7
shareholders' interests 9.5, 9.7, 9.10
short interfering RNAs (siRNAs) 2.13
silkworms, transgenic 2.10, 2.28
single molecule biophysics 2.25
slippery slope argument 4.14, 6.44
Smith, Adam 9.2
social choices 5.59–5.60
social consequences, uncertainties 3.8
social contract theory 4.17
social networking 5.12
social objectives 7.48, 7.57, 10.15
social relations, technological determinism 4.16
social scientists 5.31, 6.61
social shaping, emerging <strong>biotechnologies</strong>
9.65–9.66
social value 1.34
commercialisation and 9.52–9.54, 9.71–
9.72, 10.21
incentives reflecting 9.55–9.70
societal attitudes, accounting for 8.12–8.13
societal issues, addressing 6.36–6.37, 7.53–
7.55, 10.16
sociotechnical imaginaries 2.34–2.35
solidarity 4.30, 4.56
Spinks Report (1980) 7.4
spin-outs (spin-offs) 6.5, 6.13
influences on research 6.22
promotion of 6.39
research and profit-seeking 9.10–9.12
successful 7.4
start-ups 6.5, 6.22
steam engine 3.23, Box 3.3
stem cell research 1.22, 2.5–2.6, 2.28, 2.37,
8.22
strategic advisory bodies, UK 7.6–7.9
Strategy for UK life sciences (BIS) 7.15–7.16
A strategy for UK regenerative medicine (MRC)
7.16
submerged <strong>biotechnologies</strong> 2.42
surrogate endpoints 9.51
surveillance 8.28, 8.39
sustainability 4.31–4.32, 4.56
synthetic biology 2.2, 2.18–2.23, 6.19
bricolage approach 9.35
economic exploitability 7.40
economic growth agenda 7.13–7.15
exclusion of DIYBio groups 6.56
interdisciplinary nature 6.19, 6.61
leadership council 6.35, 7.13
parts-based (BioBricks®) 1.14, 2.19, 9.46
potential applications 7.15
regulatory aspects 8.13
roadmapping 6.32–6.35, 7.13, 7.54
visions 1.4, 2.36–2.38
vs genetic engineering 2.18
systemic risks 3.4
systems biology 6.19
tax incentives 9.52
technological change 3.22–3.25
technological determinism 4.15–4.16
technological lock-in 1.8, 1.24–1.26, 1.28, 3.24
technological momentum 1.24
technological paradigms 1.31, 3.24
technological pathways see pathways,
technological
technology control dilemma, Collingridge's
1.27–1.29, Box 1.2
Technology Strategy Board (TSB)
data provision 6.5
economic growth agenda 7.12, 7.15–7.16
funding of research 6.9, 6.10
influence of industry over 7.52
innovation platform 4.32
membership 7.52
technoscientific imaginary 2.34
technostructure 9.6
television 5.11
terraforming 2.38
terrorism Box 3.1, 8.10
therapeutic cloning 2.6
therapeutic targets
crowdsourcing 9.50, Box 9.3
validated 9.49–9.50
third industrial revolution 2.36
third stream funding 6.38
tick box ethics 4.39
timescales of emergence 2.28, 2.43, 4.50
tomatoes, genetically modified (GM) 2.8
trade associations 6.28
trade secrets 9.18, 9.21
trajectories, technological see pathways,
technological
transformative potential 3.1, 3.22–3.25, 3.37
guiding research policy 7.42–7.43
public ethics approach 4.15, 4.18–4.19
transgenic animals 2.10–2.11, 3.19
transgenic plants 9.38–9.39, 9.69
transhumanism 2.34, 3.19
transplantation 2.6, 2.11
trastuzumab 2.12
Treasury, the 6.24, 7.11, 7.56, 10.18
tunnelling problem 2.33, 2.47
type 1 emerging <strong>biotechnologies</strong> 9.34–9.36
I N D E X
207